Category: Business

As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm’s sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation.

LAS VEGAS – November 1, 2022 – (Newswire.com)

Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Food and Chemical Toxicology that demonstrates the potential of selected cannabinoids and terpenes to reduce inflammation. Finding Cannabis compounds with anti-inflammatory properties may be useful in decreasing inflammation associated with a wide range of serious human disorders, and these Cannabis compounds potentially have more favorable side effect profiles than NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), which currently lead the anti-inflammatory market based on sales. Largely because of the increasing prevalence of chronic and auto-immune inflammatory disorders, the market for anti-inflammatory therapies is expected to grow to $191.42 billion by 2027.

“We believe that this is the first demonstration of the anti-inflammatory potential of some very potent minor cannabinoids and terpenes derived from Cannabis,” said Dr. Andrea Small-Howard, President, Chief Science Officer, and Director of Gb Sciences. “The identification of cell type-specific immune modulating effects by different individual cannabinoids and terpenes was an important first step in designing our novel anti-inflammatory therapies. The results from our second study on the anti-inflammatory effects of proprietary mixtures of these ingredients will be published subsequently with our collaborators at Michigan State University and Chaminade University.”

Gb Sciences selected the specific Cannabis constituents for this study based on their prior activity within chemovar studies. To determine whether these cannabinoids and terpenes could reduce inflammation, Gb Sciences’ colleagues at Michigan State University tested the individual Cannabis constituents over a wide range of concentrations in human, primary immune cells in a co-culture system that mimics the complex interactions that regulate the human immune system. Three immune cell types were chosen as representatives within these native human immune cell mixtures based on their important roles in modulating the inflammatory cascade.

This study demonstrated that delta-9 tetrahydrocannabinol (THC) had the greatest effect on reducing inflammatory biomarkers and processes in all three immune cell types. Following THC, the greatest immune activity modulation was measured by cannabidivarin (CBDV), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), and lastly, cannabidiol (CBD) in decreasing order based on the number of statistically significant changes measured in inflammatory bioassays relative to the control. Some of these minor cannabinoids and the terpenes tested had very ‘selective’ anti-inflammatory effects, which targeted a single cell type and/or caused a change in only a single inflammatory bioassay.

This study entitled “Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes” was co-authored by Gb Sciences’ own President and Chief Science Officer, Andrea Small-Howard, and her collaborators Lance K. Blevins, Anthony P. Bach, Robert B. Crawford, Jiajun Zhou, Joseph E. Henriquez, Michael D. Rizzo, Sera Sermet, D.M. Isha Olive Khan, and Norbert Kaminski from Michigan State University (East Lansing, Michigan, USA) and Helen Turner from Chaminade University of Honolulu (Honolulu, Hawai’i, USA). The second part of this study measured the effects of proprietary mixtures of cannabinoids and terpenes on inflammation within this human, primary immune cell model, and this second study will be published next in collaboration with our colleagues at Michigan State University and Chaminade University.

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome related to COVID-19, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Contact Information:

Madeleine Moench

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients

CARY, N.C. – November 1, 2022 – (Newswire.com)

InstantGMP, the originators of the all-in-one manufacturing and quality system, is proud to welcome a new contract development and manufacturing organization, Quality Chemical Laboratories (QCL), to its growing client base.

Quality Chemical Laboratories was founded in 1998 as a raw material testing laboratory and has continuously expanded capabilities and service offerings. For over 25 years, this leading CDMO has provided GMP-compliant formulation development and manufacturing services for the pharmaceutical industry. The company’s clients range from small start-up companies to some of the most prominent pharmaceutical corporations in the world.

As its client base continues to grow, Quality Chemical Laboratories recognized the importance of implementing a new software system to enhance its processes while gaining efficiency and maintaining GMP and FDA compliance.

QCL’s exhaustive search for a new software system led the company to the InstantGMP PRO system. While the software’s all-in-one capabilities impressed the QCL team, they required computer system validation to determine if the system:

• Meets FDA Part 11 compliance.
• Achieves its intended purpose by meeting user requirements.
• Is free from any installation or performance issues that could negatively impact the integrity of the CDMO’s production cycles, raw materials or finished pharmaceutical products.

To ensure that the InstantGMP PRO system was validated, Quality Chemical Laboratories conducted an extensive software vendor audit. During the software vendor auditing process, QCL reviewed every piece of the software’s validation documentation and standard operating procedures (SOPs) via a virtual session with InstantGMP to confirm that InstantGMP PRO:

• Is properly validated.
• Vendor documentation can be appropriately leveraged to save QCL significant time and resources.
• Functions accordingly and accurately.
• Aligns with the information defined in the provided user requirement documentation.

After QCL reviewed all the respective documentation and asked any pertinent questions, it created and supplied a detailed audit report that identified topics that required further discussion and some minor issues that needed to be resolved. At the conclusion of the audit process, InstantGMP successfully satisfied Quality Chemical Laboratories’ requirements.

Not only did this process lead to a successful relationship, but it also provided the QCL team a better understanding of the software’s full capabilities. Additionally, the audit process offered InstantGMP an opportunity to address previously unidentified issues and further enhance the software with new features that best meet manufacturers’ needs.

InstantGMP is excited to provide Quality Chemical Laboratories with a validated all-in-one software system that truly meets its needs for improved processes and assured compliance. InstantGMP wishes them continued success in the contract formulation development and manufacturing industry and thanks them for helping InstantGMP enhance their software during the audit process.

To learn more about InstantGMP PRO‘s new features and software auditing processes for GMP manufacturers, contact us to schedule a demonstration.

Contact Information:

Robert Pochadt

Director of Sales

[email protected]

215-975-9660

Jeremy Hall

Technical Sales Manager

[email protected]

757-759-4500

Related Files
InstantGMP PRO for FDA Requlated Industries 4.22.pdf

Press Release Service
by
Newswire.com

Original Source:

New CDMO Client, Quality Chemical Laboratories, Benefits From InstantGMP’s All-in-One Quality & Manufacturing System and Software Auditing for GMP Manufacturers

The Social Loan Company (TSLC) is set to offer its unique credit-led neo-banking platform for the underserved in the African market.

…

Anyone can easily build a community that integrates with the web3 economy, and use various features for the web3 gaming community in the Polygon ecosystem.

…

There is one seasoning above all to make everything from vegetables, fish, and even game meat taste delicious and its Cracker Boy Seasonings. Created in 1997, Cracker Boy Seasoning has been a cult favorite among custom…

‘Sculptoris’ speaks to a high jewelry creator, her technique, and the origin of gold.

NEW YORK – October 31, 2022 – (Newswire.com)

Tess Sholom holds a legendary art jewelry past. She has worked with fashions finest couturiers, her jewelry is included in collections at the Smithsonian Institution, Museum of the City of New York, the Fashion Institute of Technology, and her permanent fashion jewelry collection is at the Met Fifth Avenue. Most recently, she has adopted a one-word title that speaks to her design technique, and her exclusive alliance with gold.

In decades past, Tess Sholom’s fashion jewelry appeared in Vogue and Harper’s BAZAAR. Her bespoke brand today offers a nod to the new; an artfully descriptive title that is personalized, memorable and legally protectable. Tess Sholom’s point of difference in 22kt gold design lead to the one-word title.

Defining Sholom as a “sculptor in gold,” was accurate, but commonplace. By combining the words “sculptor” and “is” Sculptoris^TM was formed and a trademarked title was created. Sculptors is also an extraordinary, ancient star. The same star type that Nature, the Smithsonian, and the World Gold Council have recently brought to public attention. Why? The Sculptoris^TM star will collide or self-erupt creating a supernova releasing gold and precious metals. Sculptoris^TM as a title is befitting to Tess, a 22k gold jewelry artisan who has drawn design inspiration from the heavens, and is a star in her own right.

“I use a torch and tools to mold and shape the gold, similar to how ancient Greek goldsmiths crafted jewelry and the gold in my designs could be thousands of years old. I adore working in 22k gold because it is malleable and has a beautiful, rich color,” said Tess Sholom.

Famed Hollywood director Julie Dash selected Tess Sholom’s Circe’s Circle necklace as seen on the Met Gala’s red carpet this year and covered by the Associated Press. Tess’ investment-quality 22k designs were featured at WealthXPrivate.com and currently with KnightFrankWealth.com, and ranked ‘most read September stories.’

“We wanted to unite Tess’ ancient and modern art in a fresh, dynamic approach,” said Pam Levine of Levine Luxury Branding, who worked with Luxe Licensing to create Sculptoris videos. Those videos have exceeded 40,000 organic views. “We also worked Alain Simić on an innovative lifestyle campaign showcased through Tess’ Instagram account,” Levine added.

Beyond debuting at Couture, represented through VIEWPOINTnext this year, Tess continues to sell through Mayfair Rocks in East Hampton, and the Mahnaz Collection in Manhattan. Her designs may be purchased through www.TessSholomDesigns.com or https://tinyurl.com/TessSholomOnline.

Contact Information:

Daniel Scott

Brand Architect

[email protected]

201.294.3697

Press Release Service
by
Newswire.com

Original Source:

Reigniting Tess Sholom’s 22k Art Jewelry With a Word

Partnership will bring the alarm monitoring industry’s first face-matching solution

LOS ANGELES – October 31, 2022 – (Newswire.com)

Captis Intelligence, a leading provider of I-4 crime solutions (Intelligence, Information, Investigation, Identification) announced that it has signed a global agreement with Immix Software LLC. The new partnership will integrate Captis’ ODSI solution into the Immix security monitoring software used in central stations and security monitoring centers around the world, allowing professional monitoring agents the ability to scan surveillance face-images across the exclusive Captis database of over 85 million criminals.

Headquartered in Tampa Florida, Immix is a leading worldwide developer of monitoring software installed in the world’s most demanding security operating center environments. The partnership with Captis will introduce an industry-first identification solution to the monitoring industry, continuing Immix’s commitment in delivering cutting-edge solutions tailored to the needs of their customers.

“The integrated Captis ODSI solution effectively sets the next generation of elevated intelligence for professional monitoring companies while providing a frictionless experience within the Immix platform,” said Chris Brown, CEO of Immix. “Today, companies are faced with more complex security challenges which impose higher demands on our monitoring partners” added Brown. “The unique industry-first Captis solution provides our partners with a powerful capability of identifying high-threat subjects in seconds within a legal framework of state, county, and federal open-source intelligence.”

The announcement comes in the wake of a major acceleration in growth for Captis which has surpassed 85 million database criminal files in dozens of categories including wanted suspects, sex offenders, terrorists, and financial crime violators. Captis’ roster of Fortune 500 clients continues to expand and further cement ODSI as a critical component in security operations. “We are extremely pleased to partner with Immix,” stated Dario Brebric, President of Captis. “Immix not only shares our values, innovation and passion for solving unique surveillance challenges, but are dedicated in presenting an identification solution that can result in better outcomes and save lives,” added Brebric.

 For more information on Captis Intelligence, please visit www.captisintelligence.com.

For more information on Immix, please visit www.immixprotect.com

About Captis Intelligence

Captis Intelligence’s I-4 platform (Intelligence, Information, Investigation, Identification) provides an advanced cloud-based system for public and private sector applications. Captis unifies situational awareness, geographic crime intelligence, subject identification, criminal databases, and access to solveacrime.com. A global innovator, Captis is headquartered in Los Angeles and has offices in London and Singapore. Captis was founded on the principle of innovation and remains at the forefront of pioneering I-4 crime prevention/suspect identification technologies.
 

Contact Information:

Dario Brebric

President

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Immix Signs Global Technology Agreement With Captis Intelligence

New study released by the National Institute of Health found that women who use hair straightening chemicals are 2.5 times more likely to develop uterine cancer. The Dolman Law Group is investigating claims on a nation…

Home Loan Home Loan
MELBOURNE, Australia – October 31, 2022 – (Newswire.com)

…

When it comes to facilities management, engagement with waste is often multifaceted due to the number of tenants in a building, campus or business precinct.

…